Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus and comparison of hypoglycemic action of concomitant medications: a subanalysis of the JAMP study.

ABSTRACT:

Purpose

To determine the efficacy and safety of sitagliptin when used with some therapeutic drugs to treat elderly patients.

Methods

Sitagliptin (50 mg/day) was added to the pre-existing therapy for type 2 diabetes. Changes in the glycated hemoglobin (HbA1c) level after 3 months of treatment were compared with the baseline, and exploratory analysis was performed. These analyses were conducted as subanalyses of the JAMP study, which was an open-label observational study.

Results

For patients who were ≥65 years of age, the change in HbA1c level from baseline ranged from -0.50 to -0.87% at 3 months after starting treatment. There was no significant difference in the change in HbA1c level between the patients treated with different concomitant drugs. No significant differ

SUBMITTER: Ujihara N 

PROVIDER: S-EPMC6224874 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature